Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2021 Feb 23:2021.02.22.432177.
doi: 10.1101/2021.02.22.432177.

Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection

Affiliations

Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection

Lina Ma et al. bioRxiv. .

Update in

  • Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection.
    Ma L, Sahu SK, Cano M, Kuppuswamy V, Bajwa J, McPhatter J, Pine A, Meizlish ML, Goshua G, Chang CH, Zhang H, Price C, Bahel P, Rinder H, Lei T, Day A, Reynolds D, Wu X, Schriefer R, Rauseo AM, Goss CW, O’Halloran JA, Presti RM, Kim AH, Gelman AE, Dela Cruz CS, Lee AI, Mudd PA, Chun HJ, Atkinson JP, Kulkarni HS. Ma L, et al. Sci Immunol. 2021 May 13;6(59):eabh2259. doi: 10.1126/sciimmunol.abh2259. Sci Immunol. 2021. PMID: 34446527 Free PMC article.

Abstract

Complement activation has been implicated in the pathogenesis of severe SARS-CoV-2 infection. However, it remains to be determined whether increased complement activation is a broad indicator of critical illness (and thus, no different in COVID-19). It is also unclear which pathways are contributing to complement activation in COVID-19, and, if complement activation is associated with certain features of severe SARS-CoV-2 infection, such as endothelial injury and hypercoagulability. To address these questions, we investigated complement activation in the plasma from patients with COVID-19 prospectively enrolled at two tertiary care centers. We compared our patients to two non-COVID cohorts: (a) patients hospitalized with influenza, and (b) patients admitted to the intensive care unit (ICU) with acute respiratory failure requiring invasive mechanical ventilation (IMV). We demonstrate that circulating markers of complement activation (i.e., sC5b-9) are elevated in patients with COVID-19 compared to those with influenza and to patients with non-COVID-19 respiratory failure. Further, the results facilitate distinguishing those who are at higher risk of worse outcomes such as requiring ICU admission, or IMV. Moreover, the results indicate enhanced activation of the alternative complement pathway is most prevalent in patients with severe COVID-19 and is associated with markers of endothelial injury (i.e., Ang2) as well as hypercoagulability (i.e., thrombomodulin and von Willebrand factor). Our findings identify complement activation to be a distinctive feature of COVID-19, and provide specific targets that may be utilized for risk prognostication, drug discovery and personalized clinical trials.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None of the authors have commercial affiliations or consultancies, stock or equity interests, or patent-licensing arrangements that could be considered a conflict of interest regarding the submitted manuscript.

Figures

Figure 1.
Figure 1.. Markers of complement activation are unique to COVID-19 compared to non-COVID-19 respiratory failure.
Plasma for determination of circulating markers of complement activation was obtained in patients with COVID-19 and influenza at Barnes-Jewish Hospital (BJH)/Washington University School of Medicine (WUSM). (A) CONSORT flow diagram showing patient enrollment, allocation and outcomes in the COVID-19 cohort. The CONSORT diagram for the influenza and non-COVID acute respiratory failure cohorts are in Figure S1. Box and whiskers plots of differences in sC5b-9 between (B) the influenza (EDFLU) and COVID-19 cohorts, (C) the non-COVID acute respiratory failure (Immunity in Pneumonia and Sepsis, IPS) and the COVID-19 cohorts, and (D) restricting the cohorts in Fig.1C to those who died. The center of the box represents the median value, and the length of the box represents the interquartile range. The whiskers represent the minimum and maximum values in each group. Statistical significance is determined using Mann-Whitney U test.
Figure 2.
Figure 2.. Complement activation is associated with worse outcomes in COVID-19 in two independent cohorts.
Markers of complement activation were quantified in the plasma at WUSM and Yale University School of Medicine (Yale). Box and whiskers plots of sC5b-9 levels in the WUSM COVID-19 cohort in (A) patients requiring ICU admission versus those who did not, (B) patients requiring invasive mechanical ventilation (IMV) versus those who did not, and (C) patients who died versus those who survived. (D) A linear regression line shows the relationship between plasma levels of sC5b-9 and sC5a. The spline chart demonstrates the mean with 95% confidence intervals. R2 represents the goodness-of-fit. The degree of correlation is assessed using Spearman`s Rank Correlation Coefficient test (ρ=0.4909, 95% CI 0.2321 – 0.6848, n=48). In the Yale longitudinal cohort, concurrently measured sC5a levels are utilized to compare (E) patients requiring ICU admission versus those who did not, and (F) patients requiring IMV versus those who did not. The center of the box represents the median value, and the length of the box represents the interquartile range. The whiskers represent the minimum and maximum values in each group. Statistical significance is determined using Mann-Whitney U test.
Figure 3.
Figure 3.. Alternative pathway activation is associated with worse outcomes in COVID-19.
Comparisons in the levels of components involved in the alternative pathway (AP) in plasma of patients requiring ICU admission versus those who did not, in the WUSM COVID-19 cohort, are presented using box and whiskers plots - (A) iC3b: C3 ratio, (B) Factor B, and (D) Ba. (C) A linear regression line shows the relationship between plasma levels of sC5b-9 and Factor B. The spline chart demonstrates the mean with 95% confidence intervals. R2 represents the goodness-of-fit. The degree of correlation is assessed using Spearman`s Rank Correlation Coefficient test (ρ=0.4768, 95% CI 0.2146 – 0.6749, n=48). (E) Plasma Ba levels are compared in patients who survived [1,301.0 (966.0 – 2250.0), n=29] versus those who did not [3,266 (2,368 – 6236), n=19], as are the plasma levels of Factor D (F). The center of the box represents the median value, and the length of the box represents the interquartile range. The whiskers represent the minimum and maximum values in each group. Statistical significance is determined using Mann-Whitney U test.
Figure 4.
Figure 4.. Complement activation is associated with markers of endothelial injury and a prothrombotic state in patients with COVID-19.
A linear regression line shows the relationship between plasma levels of Factor D and (A) angiopoietin-2 (Ang2), (B) thrombomodulin, and (C) von Willebrand factor antigen (vWF-Ag) in the Yale longitudinal cohort (n=49). The spline chart demonstrates the mean with 95% confidence intervals. R2 represents the goodness-of-fit. The degree of correlation is assessed using Spearman`s Rank Correlation Coefficient test between Factor D and (a) Ang2 (ρ=0.5095, 95% CI 0.2585 – 0.6960), (b) thrombomodulin (ρ=0.6050, 95% CI 0.3829 – 0.7609), and (c) vWF-Ag (ρ=0.3367, 95% CI 0.04612 – 0.5747). Box-and-whiskers plots are utilized for comparing the levels of (D) Ang2, (E) thrombomodulin, and (F) vWF Ag in plasma of patients requiring invasive mechanical ventilation (IMV) versus those who did not. The center of the box represents the median value, and the length of the box represents the interquartile range. The whiskers represent the minimum and maximum values in each group. Statistical significance is determined using Mann-Whitney U test.

References

    1. Ackermann M. et al. (2020) ‘Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19’, The New England Journal of Medicine, 383(2), pp. 120–128. doi: 10.1056/NEJMoa2015432. - DOI - PMC - PubMed
    1. Bain W. et al. (2021) ‘COVID-19 versus Non-COVID ARDS: Comparison of Demographics, Physiologic Parameters, Inflammatory Biomarkers and Clinical Outcomes’, Annals of the American Thoracic Society. doi: 10.1513/AnnalsATS.202008-1026OC. - DOI - PMC - PubMed
    1. Blanco-Melo D. et al. (2020) ‘Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19’, Cell, 181(5), pp. 1036–1045.e9. doi: 10.1016/j.cell.2020.04.026. - DOI - PMC - PubMed
    1. Bradley B. T. et al. (2020) ‘Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series’, Lancet (London, England), 396(10247), pp. 320–332. doi: 10.1016/S0140-6736(20)31305-2. - DOI - PMC - PubMed
    1. Carsana L. et al. (2020) ‘Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study’, The Lancet. Infectious Diseases, 20(10), pp. 1135–1140. doi: 10.1016/S1473-3099(20)30434-5. - DOI - PMC - PubMed

Publication types